Tyra Biosciences
TYRA
79 hedge funds and large institutions have $749M invested in Tyra Biosciences in 2024 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 16 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 16
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
3% more funds holding
Funds holding: 77 → 79 (+2)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.11% less ownership
Funds ownership: 89.21% → 89.1% (-0.11%)
3% less capital invested
Capital invested by funds: $768M → $749M (-$19.8M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.45M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$6.42M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.83M |
| 4 |
PA
Perceptive Advisors
New York
|
+$5.82M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$4.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$22.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.9M |
| 3 |
FTM
First Turn Management
Del Mar,
California
|
-$6.25M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.34M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$2.51M |
TYRA Hedge Fund Activity: Q2 2024 in Review
79 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q2 2024, worth a combined $749M — down 2.6% from $768M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TYRA positions and 16 closed out — a net gain of 2 holders — while 31 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $6.45M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $22.9M sold.
- 79 institutional investors held Tyra Biosciences (TYRA) as of Q2 2024, up from 77 in Q1 2024.
- Funds reported $749M of Tyra Biosciences stock for Q2 2024, down 2.6% quarter-over-quarter.
- 18 funds opened new Tyra Biosciences positions in Q2 2024 and 16 closed out, a net change of +2 holders.
- The largest Tyra Biosciences buyer in Q2 2024 was BlackRock, an estimated $6.45M added.
- The largest Tyra Biosciences seller in Q2 2024 was Fairmount Funds Management, an estimated $22.9M sold.
Based on aggregated 13F filings for Q2 2024.